Halozyme wins Dutch court injunction blocking Merck Keytruda SC in eight European markets over EP622 patent
Bitget2026/10/07 12:31Halozyme won a Dutch court injunction barring Merck’s Keytruda SC manufacture, sale, import, or stocking across several European markets. The Hague court found infringement of Halozyme’s EP 2,797,622 patent, rejecting Merck’s invalidity challenge. Order targets Merck’s European authorization holder MSD BV, restricting use of its marketing authorization to support affiliates. Keytruda’s IV version remains available, not covered by the injunction. Halozyme is also pursuing enforcement in Germany, where it won a preliminary injunction in December 2025, plus U.S. litigation. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Halozyme Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610070830PR_NEWS_USPR_____LA65803) on October 07, 2026, and is solely responsible for the information contained therein.
- Halozyme won a Dutch court injunction barring Merck’s Keytruda SC manufacture, sale, import, or stocking across several European markets.
- The Hague court found infringement of Halozyme’s EP 2,797,622 patent, rejecting Merck’s invalidity challenge.
- Order targets Merck’s European authorization holder MSD BV, restricting use of its marketing authorization to support affiliates.
- Keytruda’s IV version remains available, not covered by the injunction.
- Halozyme is also pursuing enforcement in Germany, where it won a preliminary injunction in December 2025, plus U.S. litigation.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Goldman Sachs dramatically lowers KOSPI target from 12,000 to 9,000 points, still insists there is 60% upside potential
Goldman Sachs strategists have lowered their 12-month target for South Korea's KOSPI Index from 12,000 points to 9,000 points, representing a 25% decrease. Earlier this year, Goldman had raised the target multiple times. The latest downgrade is due to mounting concerns in the market over artificial intelligence (AI) trading.
AI investment has not ended; wealth is simply being redistributed.
Can NEAR Protocol defend $4.30 support after a 10% price drop?
Crypto prices
More
